## [Indonesian Food and Drug Authority (BPOM) Proposes Guideline on Follow-Up Actions for Regulatory Oversight Findings on Traditional Medicines, Health Supplements, Quasi-Drugs, and Cosmetics](/index%2ephp/consumer-industry-news/indonesian-food-and-drug-authority-bpom-proposes-guideline-on-follow-up-actions-for-regulatory-oversight-findings-on-traditional-medicines-health-supplements-quasi-drugs-and-cosmetics) May 21, 2026 On May 21, 2026, the Indonesian Food and Drug Authority (BPOM) published a draft BPOM Regulation titled “Guideline on Follow-Up Actions for Regulatory Oversight Findings on Traditional Medicines, Quasi-Drugs, Health Supplements, and Cosmetics.” The draft regulation was issued as a proposed regulatory instrument and is listed under BPOM’s regulatory development program. The proposed regulation is intended to establish standardized procedures and guidance for follow-up actions resulting from regulatory inspections, monitoring activities, and enforcement findings involving traditional medicines (natural medicinal products), quasi-drugs, health supplements, and cosmetic products. The draft aims to provide a consistent framework for regulatory responses to non-compliance identified during BPOM oversight activities. According to the draft record, the regulation covers products within the OBASKKOS sector (Traditional Medicines/Natural Medicines, Health Supplements, Quasi-Drugs, and Cosmetics) and focuses on regulatory follow-up measures associated with supervision outcomes. The proposal forms part of BPOM’s ongoing efforts to strengthen post-market surveillance and compliance management for regulated health-related consumer products. Source Consumer News Region - [Asia Pacific](/index%2ephp/consumer-news-region/asia-pacific) - [Indonesia](/index%2ephp/consumer-news-region/indonesia) Consumer News Tags Indonesian Food and Drug Authority (BPOM); Draft BPOM Regulation; Traditional Medicines; Natural Medicines; Health Supplements; Quasi-Drugs; Cosmetics; Regulatory Oversight; Post-Market Surveillance; Compliance Enforcement; Regulatory Follow-Up Actions